Neurocrine and Alnylam each face investor questions about the growth potential of key franchises. Ascendis, meanwhile, saw an ...

The move drew skepticism from investors despite multiple recent research setbacks that have left questions about Sanofi’s ...

The latest in a string of clinical wins, the late-stage data gives the company strong footing to compete with BioMarin's top seller.

The microbiome specialist, which for years has struggled to stay afloat, is cutting its staff by 30% and focusing resources on earlier, immunology-focused research.

The potentially $4.4 billion deal is Madrigal’s second with a China-based biotech and hands the company six preclinical RNA ...

Moderna claimed that the decision, issued by top vaccine regulator Vinay Prasad, was “inconsistent” with prior FDA ...

CagriSema’s blood sugar and weight reductions exceeded the company’s blockbuster Wegovy, yet the drug might still struggle to ...

Kailera CEO Ron Renaud claimed the weight loss effects and safety profile observed in the study suggest its therapy could ...

Select products from Pfizer, Eli Lilly and others will be sold at a discount, although the lower costs won’t be felt by many ...

The agency’s program will be open to pharmaceutical facilities that align with “national priorities.” Elsewhere, a ...

Lilly could pay Innovent Biologics up to $9 billion in a new alliance. Elsewhere, Roche tried to assuage investor concerns about its new multiple sclerosis drug and Roivant shares surged.

Data integrity is key to the success of any cell therapy program. CDMOs can implement robust data management systems for ...